The U.S. Food and Drug Administration (FDA) has awarded breakthrough therapy status to rinatabart sesutecan (Rina-S), an investigational treatment for…
Articles by Andrea Lobo
Daraxonrasib, Revolution Medicines’ RAS inhibitor candidate for the treatment of people with advanced, or metastatic, pancreatic cancer with…
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian…
The first participant has been dosed in a Phase 1/2 trial investigating TNG456, a PRMT5 inhibitor to treat people with…
Offering genetic testing at the provider’s office at the time of diagnosis effectively increased the number of people with…
Corcept Therapeutics is launching a Phase 2 clinical trial to evaluate the safety and efficacy of relacorilant as a…
A Phase 1 clinical trial testing Nikang Therapeutics’ oral therapy NKT3964 in people with certain advanced or metastatic solid…
Calidi Biotherapeutics has begun recruiting adults with high-grade glioma for a Phase 1b/2 clinical trial to study the…
Allarity Therapeutics will soon start recruiting patients at several U.S. sites for a new dosing protocol in its Phase…
The U.S. Food and Drug Administration (FDA) has granted fast-track status to CUSP06, Oncusp Therapeutics’ treatment candidate for platinum-resistant…